Outcome of BRCA Survey Project

  • Katrina Williams
  • December 4, 2019

In July 2019, the FLASCO Board of Directors approved a Survey Initiative on BRCA testing with Merck, FLASCO Diamond Elite Member. All FLASCO Members who treat patients with breast/ovarian cancer, including APPs, were asked to complete the survey.  The goal of the project was to identify the needs in order to increase awareness and utilization of recommended molecular testing upon diagnosis through collaboration with pathologists, oncologists, and other FLASCO members.

Results showed, that compared to Standard of Care (SOC) nationally recognized guidelines (ex: NCCN), that a gap exists with patients and providers alike.  Concern is that Ovarian and Breast patients are being missed: treatment options, familial impact, precision approaches.  The results of the survey were presented as a poster presentation during the 2019 FLASCO Fall Session (PDF of poster).

Merck and FLASCO share the ASCO triple aim of matching the right patient to the right drug at the right time and believe this project can further that objective. Merck/AstraZeneca developed and shared a non-branded electronic resource that can be utilized by providers and patients, in both English and Spanish, that highlights why BRCA testing in ovarian and breast patients is so important: BeBRACA Aware (English) or BeBRACA Aware (Spanish)

© 2021 FLASCO | Premium Website Design by The HDG

FLASCO